Search hospitals > Ontario > TORONTO

Novartis Investigative Site

Claim this profile
TORONTO, Ontario M5G 2M9
Global Leader in Breast Cancer
Global Leader in Skin Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
222 reported clinical trials
0 medical researchers
Photo of Novartis Investigative Site in TORONTOPhoto of Novartis Investigative Site in TORONTOPhoto of Novartis Investigative Site in TORONTO

Summary

Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Non-Small Cell Lung Cancer and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 235 conditions. There are 0 research doctors associated with this hospital, such as .

Area of expertise

1Breast Cancer
Global Leader
Novartis Investigative Site has run 25 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 negative
2Skin Cancer
Global Leader
Novartis Investigative Site has run 23 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
BRAF positive
PD-L1 positive

Top PIs

Clinical Trials running at Novartis Investigative Site

Breast Cancer
Prostate Cancer
Skin Cancer
Lupus
Colorectal Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lymphoma
Follicular Lymphoma
Acute Lymphoblastic Leukemia
Image of trial facility.

[177Lu]Lu-NeoB + Capecitabine

for Metastatic Breast Cancer

In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).
Recruiting1 award Phase 1 & 25 criteria
Image of trial facility.

Radioactive Drugs

for Breast Cancer

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).
Recruiting1 award Phase 15 criteria
Image of trial facility.

ECI830 + Ribociclib + Fulvestrant

for Breast Cancer

Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Recruiting1 award Phase 1 & 25 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Novartis Investigative Site?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security